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October 20121180 AbstractsComparison of Long-term Survival After Open vs Endovascular Repair
of Intact Abdominal Aortic Aneurysm Among Medicare Beneficiaries
Jackson RS., Chang DC., Freischlag JA.. JAMA 2012;307:1621-8.
Conclusion: In Medicare beneficiaries, repair of isolated, intact ab-
dominal aortic aneurysms (AAA) by endovascular means is associated with a
lower risk of all-cause mortality and AAA-related mortality than repair using
open techniques.
Summary: Randomized clinical trials (RCTs) have failed to demon-
strate a long-term survival advantage of endovascular repair vs open repair of
AAA. Furthermore, a previous study of Medicare beneficiaries undergoing
AAA repair between 2001 and 2004 also failed to demonstrate a survival
advantage of endovascular repair over open repair beyond 3 years of
follow-up (Schemerhorn ML et al, N Engl J Med 2008;358:464-74). It is
possible current endovascular devices may provide improved overall results
of endovascular repair than those available for analysis of endovascular vs
open AAA repair in the previous study of Medicare beneficiaries. The
authors, therefore, decided to compare overall and AAA-specific mortality,
readmission, and reintervention after endovascular vs open repair of non-
ruptured AAAs in Medicare beneficiary patients using a database from 2003
to 2007. This was a retrospective analysis of patients aged 65 years in the
Medicare standard analytic file, 2003 to 2007, who underwent isolated
repair of an intact AAA. The national death index was used to determine
cause of death. Primary outcome was all-cause mortality. Secondary out-
comes were AAA-related mortality, hospital length of stay, 1-year readmis-
sion, repeat AAA repair, incisional hernia repair, and lower extremity ampu-
tation. The Medicare standard analytic files contained data from a 5%
example of Medicare inpatient discharges. The study included 4029 pa-
tients; of these, 703 underwent open repair and 3826 underwent endovas-
cular repair. Mean and median follow-up times were 2.6 (SD, 1.5) and 2.5
(interquartile range, 2.4) years, respectively. After adjusting for emergency
admission, age, calendar year, sex, race, and comorbidities, there was a
higher risk of both all-cause mortality (hazard ratio, 1.24; 95% confidence
interval [CI], 1.05-1.47; P  .01) and AAA-related mortality after open vs
endovascular repair (hazard ratio, 4.37l; 95% CI, 2.51-7.66; P  .001).
Adjusted hospital length of stay averaged 6.5 days (95% CI, 6.0-7.0 days;
P  .001) longer after open repair (mean, 10.4 days) compared with
endovascular repair (mean, 3.6 days). Need for incisional hernia repair was
higher after open AAA (P .001). The 1-year readmission rates, repeat AAA
repair, and lower extremity amputation did not differ by repair type.
Comment: The data presented here do not demonstrate inferiority of
endovascular vs open AAA repair. However, there are really too many
deficiencies in the data to justify a conclusion that the data demonstrate
superiority of endovascular vs open repair of AAAs. First, follow-up is
relatively short and the number of patients analyzed quite small compared
with the number potentially available for analysis. In addition, the Medicare
database does not contain information about aneurysm configuration and
other anatomic factors that may influence surgeon choice of endovascular or
open repair. Given the general acceptance of endovascular repair, it is quite
likely many—if not most—of the patients undergoing open repair were
judged not suitable for endovascular repair. The report compares survival
after open or endovascular repair but not necessarily in patients suitable for
either open or endovascular repair. The report does not adequately address
reinterventions. Most patients undergo reinterventions for failure of endo-
vascular repair as outpatients, which was not analyzed in this study, and
reinterventions for open and endovascular aneurysm graft-related failure
requiring readmission tend to occur beyond the median follow-up of this
report (Kelso RL et al, J Vasc Surg 2009;49:589-95; and Brinster CJ et al, J
Vasc Surg 2011;54:42-6). The most reasonable conclusion provided by the
data is that endovascular repair as a form of management of AAA is a
reasonable approach for management of anatomically suitable patients with
AAA who are Medicare beneficiaries. The data are not suitable for cost-
analysis or analysis of all relevant reinterventions.
Long Term Outcomes in Men Screened for Abdominal Aortic Aneu-
rysm: Prospective Cohort Study
Duncan JL., Harrild KA., Iversen L., et al. BMJ 2012;344:e2958 [doi:
10.1136/bmj,e2958].
Conclusion: Men with abdominal aortic aneurysm (AAA) and those
with abdominal aortic diameters between 25 and 29 mm have increased risk
of mortality and subsequent hospital admission compared with men with
abdominal aortas with diameters 24 mm.
Summary: Screening ultrasound studies of men aged 65 years have
been shown to be cost-effective in reducing aortic aneurysm-related mortal-
ity, with benefits extending to at least 10 years (Thompson SG et al, BMJ
2009;338:b2307). However, aneurysm screening does not reduce all-cause
mortality, and this may be partly due to increased risk of mortality of other
vascular disease in patients with AAA (Brady AR et al, Arterioscler Thromb
Vasc Biol 2001;21:1203-7). Most screening studies use a threshold aortic
diameter of 30 mm as the definition of an AAA. Patients with abdominal
aortas at or above this level are entered into a follow-up program, and those
with abdominal aortas 30 mm are reassured and not reappointed for
t
tollow-up. However, there is a possible association between aortic diameter
nd mortality, suggesting that patients just below the threshold level of 30
m for continued aortic follow-up may still be at an increased risk for
ascular-related events (Freiberg MS et al, Circulation 2008;117:1010-7).
he authors therefore examined morbidity and mortality in men with an
AA (aortic diameter30 mm) and those with ectatic aortas (range, 25-29
m), and comparedmorbidity andmortality rates withmen with abdominal
ortas 24 mm at the time of the initial aneurysm screening study. The
tudy was performed in a large, sparsely populated area of Scotland and
ncluded 8146 men aged 65 to 74 years. The main outcome measure was
orbidity and mortality with respect to the abdominal aorta in three size
ategories:24, 25-29, and30 mm. After screening, 414 men (5.1%) had
n AAA with an aortic diameter of 30 mm, 696 (8.2%) had aortic
iameters of 25 to 29 mm, and 7063 (86.7%) had aortic diameters of 24
m. The men were followed up for a median of 7.4 years (interquartile
ange, 6.9-8.2 years). There was a significant association of aortic diameter
ith mortality: 512 deaths (7.2%) occurred in the group with aortas of24
m diameter compared with 69 deaths (10.3%) in the 25- to 29-mm group
nd 73 deaths (17.6%) in men with aortic diameters30mm.Differences in
ortality were significant, with the mortality risk in men with an aneurysm
nd in those with an aorta measuring 25 to 29 mm being significantly higher
han in men with aortas24 mm.Mortality risk in the 25- to 29-mm group
as reduced after taking into account confounders such as smoking and
nown heart disease. However, after adjustment, risk of hospital admission
or cardiovascular disease and chronic obstructive pulmonary disease was
igher in men with an aneurysm and in men with aortas measuring 25 to 29
m compared with men with an aortic diameter of 24 mm. Men with
neurysms had an increased risk of hospitalization for atherosclerotic periph-
ral artery disease, cerebrovascular disease, and respiratory disease. In men
ith aortas of 25 to 29 mm, risk of hospital admission was also higher than
nmenwith an aorta of24mm (adjusted hazard ratio, 6.7; 95% confidence
nterval, 3.42-13.2). This increased risk became apparent 2 years after
creening.
Comment: The data indicate that it is possible to stratify risks of
ardiovascular disease by abdominal aortic diameter. Patients with AAA,
bdominal aortas 30 mm, have an increased risk of cardiovascular disease
ompared with patients with abdominal aortas 24 mm. Those patients
ith aortic diameters of 25 to 29mm have an increased risk of cardiovascular
isease, but the risk disappears when confounders, such as smoking and
ypertension, are taken into account. However, patients with 25- to 29-mm
ortas still have an increased subsequent risk of hospital admission due to
ypertension, ischemic heart disease, heart failure, diabetes mellitus, and
hronic obstructive pulmonary disease. The data indicate these patients
hould not be just reassured and sent on their way. Targeted interventions to
educe subsequent hospital admissions for hypertension, ischemic heart
isease, heart failure, etc, would seem appropriate in the group of patients
ith abdominal aortas of between 25 and 29 mm in diameter.
egistry of Transcatheter Aortic-Valve Implantation in High-Risk
atients
ilardM., Eltchaninoff H., Lung B., and the France 2 Investigators. N Engl
Med 2012;336:1705-15.
Conclusion: “Real-life” experience of transcatheter aortic valve im-
lantation (TAVI) in elderly patients, with a high prevalence of coexisting
llnesses, demonstrates acceptable complication rates.
Summary: Aortic stenosis is the most frequently diagnosed valvular
ardiac condition. In elderly patients at good risk, operative mortality after
ortic valve placement is low but increases dramatically with severity of
oexisting illnesses (Melby SJ et al. Ann Thorac Surg 2007;83:1651-7).
ribier et al implanted the first transcatheter aortic valve 10 years ago
Circulation 2002;106:3006-8). Since then, 50,000 patients have been
reated by TAVI around the world. One randomized trial compared TAVI
ith medical therapy in patients where surgery was contraindicated (Leon
B et al, N Engl J Med 2010;363:1597-607). Most TAVI data is therefore
egistry data. In France, the France 2 registry is a prospective multicenter
tudy of the French experience with TAVI. In this report, all TAVIs
reformed in France, as listed in the France 2 registry, were prospectively
nalyzed with a primary end point of death from any cause. Between January
010 and October 2011, at 34 centers, 3,195 patients (49% women) were
nrolled in the France 2 TAVI registry. Median age was 82.7 7.2 years. All
atients were considered at high surgical risk for open aortic valve replace-
ent and were considered to be severely symptomatic. Edwards SAPIEN
nd Medtronic Core Valve devices were implanted in 66.9% and 33.1% of
atients, respectively. Approaches were transarterial, (femoral, 74.6%; sub-
lavian, 5.8%; other, 1.8%) or transapical (17.8%). Procedural success rate
as 96.9%. The death rate was 9.7% at 30 days and 24.0% at 1 year. The
ncidence of stroke at 1 year was 4.1%, and incidence of periprosthetic aortic
egurgitation at 1 year was 64.5%. In a multivariate model, a higher logistic
isk score on the European System for Cardiac Operative Risk Evaluation
EuroSCORE) and New York Heart Association functional class III or IV,
he use of transapical TAVI, and a higher amount of periprosthetic regurgi-
ation all were significantly associated with reduced survival.
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Volume 56, Number 4 Abstracts 1181Comment:At this point, vascular surgeons are not likely to be involved
with the selection of patients for TAVI. However, TAVI will become more
widely performed in the U.S. during the next few years as approved devices
are gradually disseminated to selected hospitals. Because the devices can
require large introducer sheaths (up to 24F) and the transapical approach
appears to be associated with higher mortality, vascular surgeons may be
involved with selection of access for placement of these devices and treat-
ment of the complications of transfemoral or trans-subclavian access. At this
point, major vascular complications in patients undergoing TAVI via the
transfemoral approach appear to occur in about 5.5% of the cases. It also
appears that in Europe, patients are increasingly opting for TAVI rather than
open aortic valve replacement, and there are suggestions of a high rate of
off-label use of the device (Zahn R et al, Eur Heart J 2011;32:198-204).
Vascular surgeons should be aware of the complexity of these patients, access
options, and the complications and outcomes of TAVI.
Stroke Recurrence Within the Time Window Recommended for Ca-
rotid Endarterectomy
Marnane M., Chroinin DN., Callaly E., et al. Neurology 2011;77:738-43.
Conclusion: Patients with asymptomatic carotid stenosis (CS) can
have recurrent strokes within the recommended treatment period of 14 days.
Summary:There is time-dependent benefit of surgery for patients with
symptomatic CS, with maximum benefit when treatment is within 2 weeks
and minimal benefit for those treated after 12 weeks (Rothwell PM et al,
Lancet 2004;363:915-24). Multiple guidelines from surgical and medical
societies now recommend endarterectomy within 14 days of symptoms
referable to a cervical CS. There are however, only a few population based
studies regarding the risk of stroke recurrence within the 14-day period
recommended for endarterectomy (Fairhead JF et al, Neurology 2005;65:
371-5). No population-based studies have evaluated recurrence risk within
72 hours of symptoms. In this study, the authors hypothesized ischemic
stroke associated with CS would have a high early recurrence rate. They
attempted to qualify this recurrence rate by using a population-based pro-
spective cohort study design with patients from the North Dublin popula-
tion stroke study. Ischemic strokes were identified over a 1-year period and
categorized into those with and without CS, with CS defined as an ipsilateral
CS with50% luminal narrowing. Stroke recurrence not associated with any
procedure was determined at 72 hours and at 7 and 14 days. A total of 365
patients had an ischemic stroke and carotid imaging. There were 51 exclu-
sions because the stroke involved the posterior circulation, was nonlateral-
izing, or was associated with ipsilateral carotid occlusion or an intracranial
CS. Of the 314 patients included for analysis, there were 36 CS-positive and
278 CS-negative strokes. Recurrent stroke occurred in 5.6% (2 of 36) of
CS-positive patients and in 0.4% (1 of 278) of CS-negative patients within
72 hours of symptom onset (P .003). At 7 days, recurrent stroke occurred
in 5.6% (2 of 36) of CS-positive patients and in 0.7% (2 of 278) of
CS-negative patients (P  .001). At 14 days, recurrent stroke occurred in
8.3% (3 of 36) of CS-positive patients and in 1.8% (5/278) of CS-negative
patients. With multivariable Cox regression analysis, CS was the only inde-
pendent predictor of recurrence at 72 hours (adjusted hazard ratio [HR],
36.1; 95% confidence interval [CI], 1.6-837.5; P  .03) and was also the
only independent predictor of recurrence at 7 days (HR, 9.1; 95% CI,
1.1-79.2; P  .05). There was also a trend at 14 days for CS being an
independent predictor of recurrence (HR, 4.6; 95% CI, 0.9-22.8; P .06).
Comment: The data indicate that in some stable patients who are
suitable candidates for endarterectomy, urgent surgery within a few days of
symptoms may prevent early stroke recurrence. A recent systematic review
also concluded there is no difference in risk of stroke or death in neurologic
stable patients who undergo endarterectomy within 1 week compared with
c
tlater time (Rerkasem K, Rothwell PN, Stroke 2009;40:e564-72). The
bvious limitation of the data here is the low number of recurrent events,
esulting in statistically significant conclusions but with wide confidence
ntervals. Additional population-based studies looking at early stroke recur-
ence are required to confirm the relatively weak statistical conclusions of this
eport.
enous Thrombosis in Users of Non-Oral Hormonal Contraception:
ollow-Up Study, Denmark 2001-10
idegaard O., Nielsen LH., Skovlund CW., et al. BMJ 2012;344:e2990
doi: 10.1136/bmj.e2990].
Conclusion:Women who use transdermal patches or vaginal rings for
ontraception have approximately a six to seven times increased risk of
enous thromboembolism (VTE) compared to women who do not use
ormonal contraception.
Summary: It is well known oral contraceptive agents increase the risk
f VTE. There are, however, little to no data regarding the effects of
ethods other than pills to deliver hormonal contraceptive agents. Such
ethods include transdermal patches, subcutaneous implants, and vaginal
ings. The authors used a historic national registry in a cohort study design
o assess absolute and relative risk of VTE in Danish women using nonoral
ormonal contraception. This national registry-based cohort study used
our national registries from Denmark. All Danish nonpregnant women
ged 15 to 49 years (n  1,626,158), who were free of previous VTE or
ancer, were followed up from 2001 to 2010. The main outcome measures
ere incidence rates of VTE in users of transdermal, vaginal, intrauterine, or
ubcutaneous hormonal contraception. Relative risk of venous thrombosis
as compared with nonusers of hormonal contraception, and rate ratios of
enous thrombosis in current users of nonoral products were compared with
he standard reference of an oral contraceptive with levonorgestrel and
strogen (30-40 g). A diagnosis of VTE was considered confirmed if there
as at least 4 weeks of anticoagulation therapy after the initial VTE diagno-
is. There were 5,287 first ever VTE events recorded within 9,429,128
omen-years of observation. Of these VTE events, 3,434 were confirmed.
he rate of confirmed VTE events was 2.1/10,000 years in nonusers of
ormonal contraception. After adjustment for age, calendar year, and edu-
ation, the relative risks and 95% confidence interval (95% CI) of confirmed
TE in users of transdermal combined contraceptive patches and vaginal
ing compared with nonusers of hormonal contraception were 7.9 (3.5-
7.7) and 6.5 (7.4-8.9), respectively. Corresponding incidence events per
0,000 exposure-years were 9.7 and 7.8 events. The relative risk (95% CI)
as increased in women who used subcutaneous implants (1.4 [0.6-3.4])
ut not in those who use the levonorgestrel intrauterine system (0.6 [0.4-
.8]). Compared with users of combined oral contraceptives containing
evonorgestrel, the adjusted relative risk (95% CI) of VTE was 2.3 (1.0-5.2)
n users of transdermal patches and 1.9 (1.3-2.7) in users of the vaginal ring.
Comment: In the last paragraph of the discussion portion of this article
he authors succinctly point out the implications of their study, “if the
ncidence rate of venous thrombosis in women using combined oral contra-
eptives containing levonorgestrel is 6 per 10,000 exposure years, that of the
aginal ring is 11 per 10,000 exposure years, and that of the transdermal
atch is 14 per 10,000 exposure years, then 2000 women using the vaginal
ing, and 1250 using the transdermal patch should shift to combined oral
ontraceptives with levonorgestrel to prevent 1 event of VTE in one year. A
isk of 10 per 10,000 years implies a risk of VTEmore than 1% over a 10 year
ser period. Therefore, women are generally advised to use combined oral
ontraceptives with levonorgestrel or norgestimate, rather than to use
ransdermal patches or vaginal rings.”
